Phospho-Tau Aggregation Biomarkers for Early Alzheimer’s Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for Alzheimer's disease (AD) are invasive, expensive, and lack effective biomarkers for early detection, particularly for mild cognitive impairment (MCI), and there is a need for noninvasive, cost-effective tools to differentiate AD from other neurodegenerative diseases.
Innovation Solution
Development of novel phospho-tau aggregation-based biomarkers, such as p-tau198, p-tau212/214, p-tau262/263, p-tau356, p-tau396, and p-tau422, detected using Western blotting and ELISA assays, to identify tau phosphorylation and hyperphosphorylation patterns in brain tissues for AD diagnosis and differentiation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If post-mortem neuropathological examination is used for definitive AD diagnosis, then diagnostic accuracy is improved, but invasiveness increases and cost increases
Solution Approach 1:
The patent uses phospho-tau biomarkers as intermediary substances that can be detected in accessible body fluids (CSF, plasma) to indirectly indicate the presence of neurofibrillary tangles in the brain, avoiding direct brain examination while maintaining diagnostic accuracy
Solution Approach 2:
The patent creates a copy of the pathological signature by detecting phospho-tau aggregates in peripheral fluids that mirror the tau pathology in brain tissue, allowing diagnosis without direct tissue examination
2Measurement precision
If positron emission tomography imaging biomarkers are used for AD diagnosis, then diagnostic capability is improved, but cost increases
Solution Approach 1:
The patent employs inexpensive phospho-tau biomarker assays that can be performed on routine clinical samples, replacing expensive imaging procedures while maintaining diagnostic effectiveness
Solution Approach 2:
The patent shifts the detection parameter from imaging signals requiring expensive equipment to biochemical marker concentrations that can be measured using standard laboratory techniques
3Measurement precision
If current phospho-tau biomarkers (p-tau181, p-tau217) are used for AD diagnosis, then differentiation from non-AD is improved, but early MCI detection capability is insufficient
Solution Approach 1:
The patent segments the tau protein analysis into multiple specific phospho-epitopes (p-tau198, p-tau212/214, p-tau262/263, p-tau356, p-tau396, p-tau422), each potentially marking different stages of tau pathology progression, enabling detection at earlier disease stages
Solution Approach 2:
The patent adds a new dimension to tau biomarker analysis by targeting multiple phospho-epitopes simultaneously, creating a more comprehensive profile that captures early pathological changes missed by single-epitope markers
4Measurement precision
If comprehensive panel of site-specific phospho-tau antibodies is used for biomarker discovery, then biomarker specificity is improved, but device complexity increases
Solution Approach 1:
The patent develops a universal screening approach using a panel of phospho-tau antibodies that can identify multiple disease-specific biomarkers simultaneously, making the complex system adaptable to different diagnostic needs
Solution Approach 2:
The patent employs a comprehensive panel of antibodies exceeding what a single assay would require, allowing selection of the most specific markers for each diagnostic application, thereby managing complexity through selective utilization
Data Source
AI summary
Provided are methods of phospho-tau aggregation-based biomarker discovery, and new utilities for discovered biomarkers in Alzheimer's disease (AD) diagnosis, differentiation, and treatment. Novel p-tau sites, p-tau198, p-tauS356, p-tau396, and p-tau422, identified through such methods showed comparable or superior characteristics with established p-tau biomarkers, and identified biomarkers were capable of differentiating AD or mild cognitive impairment (MCI) from cognitively normal controls.